The Pretreatment Albumin to Globulin Ratio As a Significant Predictor in Patients with Diffuse Large B Cell Lymphoma.

Wenqin Yue,Bin Liu,Lei Gao,Miaoxia He,Jianmin Wang,Weiping Zhang,Li Chen,Xiaoxia Hu,Lili Xu,Jianmin Yang
DOI: https://doi.org/10.1016/j.cca.2018.07.015
IF: 6.314
2018-01-01
Clinica Chimica Acta
Abstract:Background: The pretreatment albumin to globulin ratio (AGR) has been used to predict survival in several types of tumors. However, whether AGR can predict outcomes in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. We evaluated the prognosis value of AGR in DLBCL patients. Methods: We retrospectively analyzed the available serum biochemical results of 335 patients with newly diagnosed DLBCL before treatment. The AGR was calculated as: albumin (g/L)/globulin. X-tile program was used to generate an optimal cut-off value of 1.3 for AGR. And all patients were respectively divided into the low AGR and high AGR groups according to the cut-off value. Results: The low AGR group displayed more adverse clinical chacteristics, including old age, sex (female), increased beta 2-microglobulinpoor (beta 2-MG), increased lactate dehydrogenase (LDH), B symptoms, poor performance status (PS), advanced stage, number of extranodal sites >= 2 and higher International Prognostic Index (IPI). AGR was negatively correlated with age, IPI score, ECOG score, Ann Arbor stage, B symptoms, beta 2-MG, LDH, and extranodal involvement, while positively correlated with gender. Patients with a low AGR presented with significantly poorer overall survival (OS, P = .001). Multivariate analysis further demonstrated that a low AGR was an independent adverse predictor for OS (HR = 0.613; 95% CI = 0.412-0.910, P = .015). In addition, AGR distinguished patients with different prognosis in stage III-IV and the non-germinal center B cell-like lymphoma (non-GCB) groups, a low AGR was also significantly associated with poor OS in 2 groups. Conclusion: Pretreatment AGR was a simple and effective clinical marker of survival in patients with DLBCL, and may had an additional prognostic value based on Ann Arbor stage and cell of origin for DLBCL.
What problem does this paper attempt to address?